Alzheimer’s Disease (AD) is arguably one of the most complex and debilitating neurodegenerative diseases. It is generally characterized not only by neuroinflammation and oxidative stress, but also by the accumulation of amyloid-β and tau hyperphosphorylation. Because current treatments do not stop, reverse, or sometimes even slow the progression of the disease, more effective treatments are needed.
A new study (February 2017) from Frontiers in Pharmacology, discusses how cannabidiol (CBD), which has demonstrated neuroprotective, anti-inflammatory, and antioxidant properties, is non-psychoactive and may be an effective treatment option for those struggling with AD. The study found that CBD demonstrates the ability to reduce reactive gliosis and the neuro-inflammatory response. Additionally, it may promote neurogenesis.
An important fact to note is that CBD was also found to reverse and prevent the development of cognitive deficits in AD rodent models. This means that CBD could be used for the prevention of AD as well as a treatment.
The study then stated:
“Interestingly, combination therapies of CBD and Δ9-tetrahydrocannabinol (THC), the main active ingredient of cannabis sativa, show that CBD can antagonize the psychoactive effects associated with THC and possibly mediate greater therapeutic benefits than either phytocannabinoid alone. The studies provide “proof of principle” that CBD and possibly CBD-THC combinations are valid candidates for novel AD therapies. Further investigations should address the long-term potential of CBD and evaluate mechanisms involved in the therapeutic effects described.”
It is encouraging that studies are being done to find new treatments and preventions for this disease. Over 33 million people suffer from AD currently, and that number is expected to reach 115 million by year 2050. CBD may result in treatments not just for AD, but other diseases/disorders as well. As the article states:
CBD has been found in vitro to be neuroprotective, to prevent hippocampal and cortical neurodegeneration, to have anti-inflammatory and antioxidant properties, reduce tau hyperphosphorylation and to regulate microglial cell migration. Furthermore, CBD was shown to protect against Aβ mediated neurotoxicity and microglial-activated neurotoxicity, to reduce Aβ production by inducing APP ubiquination and to improve cell viability. These properties suggest that CBD is perfectly placed to treat a number of pathologies typically found in AD.
That’s Natural products contain cannabinoids and terpenes which makes them full spectrum. Each one of us has an endocannabinoid system, which is fueled by these cannabinoids and terpenes. The combination of these compounds help to provide what is known as the entourage effect. By providing pure, potent, and trusted products, That’s Natural continues to strive to meet our customers needs – something we have been doing for over ten years! With 100% traceability of where our hemp comes from, you can be confident in what you are putting on, or in, your body. For more questions regarding our CBD products, please visit our Questions and Answers page.
Categories: Research on CBD (Cannabidiol)